Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma-associated antigen MART-1/Melan-A

International Journal of Cancer

Volumn 81, Issue 6, 1999, Pages 979-984

  Jäger, Elke ^a   Höhn, Hanni ^b   Karbach, Julia ^a   Momburg, Frank ^c   Castelli, Chiara ^d   Knuth, Alexander ^a   Seliger, Barbara ^b   Maeurer, Markus J ^b,e  

^a KRANKENHAUS NORDWEST   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e Hochhaus Am Augustusplatz ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A2 ANTIGEN; MELANOMA ANTIGEN; PEPTIDE;

ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; INTERFERON PRODUCTION; MELANOMA CELL; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; CLONE CELLS; CYTOTOXICITY, IMMUNOLOGIC; HLA-A2 ANTIGEN; HUMANS; INTERFERON TYPE II; MELANOMA; NEOPLASM PROTEINS; PROTEIN ISOFORMS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032968598     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990611)81:6<979::AID-IJC22>3.0.CO;2-Y     Document Type: Article

References (33)

1. BARRON, K.S. and ROBINSON, M.A., The human T cell receptor variable gene segment, TCRBV6S1 has two null alleles. Hum. Immunol., 40, 17-19 (1994).
2. BOON, T. and VAN DER BRUCCEN, P., Human tumor antigens recognized by T lymphocytes. J. exp. Med., 183, 725-729 (1996).
3. + cytotoxic T lymphocytes. J. exp. Med., 181, 363-368 (1995).
4. CHOMCZYNSKI, P. and SACCHI, N., Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162, 156-159 (1987).
5. COULIE, P.G., BRICHARD, V., VAN PEL, A., WOLFEL, T., SCHNEIDER, J., TRAVERSARI, C., MATTHEI, S., DE PLAEN, E., LURQUIN, C., SZIKORA, .J.P., RENAULD, J.C. and BOON, T., A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. exp. Med., 180, 35-42 (1994).
6. COX, A.L., SKIPPER, J., CHEN, Y., HENDERSON, R.A., DARROW, T.L., SHABANOWITZ, J., ENGELHARD, V.H., HUNT, D.F. and SLINGLUFF, C.L., JR., Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science, 264, 716-719 (1994).
7. DANOS, O. and MULLIGAN, R.C., Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc. nat. Acad. Sci. (Wash.), 85, 6460-6464 (1988).
8. GENEVEE, C., DIU, A., NIÉRAT, J., CAIGNARD, A., DIETRICH, P.Y, FERRADINI, L., ROMAN-ROMAN, S., TRIEBEL, F. and HERCEND, T., An experimentally validated panel of subfamily-specific oligonucleotide primers (V alpha 1-w29/V beta 1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction. Europ. J. Immunol., 22, 1261-1269 (1992).
9. KAWAKAMI, Y., ELIYAHU, S., SAKAGUCHI, K., ROBBINS, P.F., RIVOLTINI, L., YANNELLI, J.R., APPELLA, E. and ROSENBERG, S.A., Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. exp. Med., 180, 347-352 (1994).
10. KNUTH, A., DANOWSKI, B., OETTGEN, H.F. and OLD, L.J., T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc. nat. Acad. Sci. (Wash.), 81, 3511-3515 (1984).
11. LEHNER, P.J., WANG, E.G., MOSS, P.A., WILLIAMS, S., PLATT, K., FRIEDMAN, S.M., BELL, J.I. and BORYSIEWICZ, L.K., Human HLA-A0201-restricted cytotoxic T lymphocyte recognition of influenza A is dominated by T cells bearing the V beta 17 gene segment. J. exp. Med., 181, 79-91 (1995).
12. LIVINGSTON, P.O., SHIKU, H., BEAN, M.A., PINSKY, C.M., OETTGEN, H.F. and OLD, L.J., Cell-mediated cytotoxicity for cultured autologous melanoma cells. Int. J. Cancer, 24, 34-44 (1979).
13. LOFTUS, D.J., SQUARCINA, P., NIELSEN. M.B., GEISLER, C., CASTELLI, C., ODUM, N., APPELLA, E., PARMIANI, G. and RIVOLTINI, L., Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MARTI(27-35). Cancer Res., 58, 2433-2439 (1998).
14. MACKENSEN, A., FERRADINI, L., CARCELAIN, G., TRIEBEL, F. FAURE, F., VIEL, S. and HERCEND, T., Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. Cancer Res., 53, 3569-3573 (1993).
15. MAEURER, M.J., CHAN, H., KARBACH, J., SALTER, R., LOTZE, M.T. and STORKUS, W.T., Amino acid substitutions at positions 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV specific cytotoxic T-lymphocytes (CTL). Europ. J. Immunol., 26, 2613-2623 (1996).
16. MAEURER, M.J., MARTIN, D.M., STORKUS, W.J. and LOTZE, M.T., Evidence for shared TCR usage in CTL recognizing HLA-A2 presented antigens shared by melanoma and melanocytes. Immunol. Today, 16, 603-604 (1995).
17. MARINCOLA, F.M., The multiple ways to tumor tolerance. J. Immunother., 20, 178-179 (1997).
18. MOMBURG, F., ROELSE, J., HOWARD, J.C., BUTCHER, G.W., HÄMMERLING, G.J. and NEEFJES, J.J., Selectivity of MHC-encoded peptide transporters from human, mouse and rat. Nature (Lond.), 367, 648-651 (1994).
19. MOSS, P.A., ROWLAND-JONES, S.L., FROHSHAM, P.M., MCADAM, S., GIANGRANDE, P., MCMICHAEL, A.J. and BELL, J.I., Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors. Proc. nat. Acad. Sci. (Wash.), 92, 5773-5777 (1995).
20. NANDA, N.K., ARZOO, K.K., GEYSEN, H.M., SETTE, A. and SERCARZ, E.E., Recognition of multiple peptide cores by a single T cell receptor. J. exp. Med., 182, 531-539 (1995).
21. PUISIEUX, I., EVEN, J., PANNETIER, C., JOTEREAU, F., FAVROT, M. and KOURILSKY, P., Oligoclonality of tumor-infiltrating lymphocytes from human melanomas. J. Immunol., 153, 2807-2818 (1994).
22. RIVOLTINI, L., KAWAKAMI, Y., SAKAGUCHI, K., SOUTHWOOD, S., SETTE, A., ROBBINS, P.F., MARINCOLA, F.M., SALGALLER, M.I., YANNELLI, J.R., APPELLA, E. and ROSENBERG, S.A., Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. ImmunoL, 154, 2257-2265 (1995).
23. RIVOLTINI, L., LOFTUS, D.J., SQUARCINA, P., CASTELLI, C., RINI, F., ARIENTI, F., BELLI, F., MARINCOLA, F.M., GEISLER, C., BORSATTI, A., APPELLA, E. and PARMIANI, G., Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivity. Crit. Rev. Immunol., 18, 55-63 (1998).
24. ROMERO, P., PANNETIER, C., HERMAN, J., JONGENEEL, C.V., CEROTTINI, J.C. and COULIE, G., Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1.A1. J. exp. Med., 182, 1019-1028 (1995).
25. ROSENBERG, S.A. and 15 OTHERS, Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature (Med.), 4, 321-327 (1998).
26. SELIGER, B., MAEURER, M.J. and FERRONE, S., TAP off-tumors on. Immunol. Today, 18, 292-299 (1997).
27. SENSI, M., TRAVERSARI, C., RADRIZZANI, M., SALVI, S., MACCALLI, C., MORTARINI, R., RIVOLTINI, L., FARINA, C., NICOLINI, G., WOLFEL, T. and PARMIANI, G., Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1. Proc. nat. Acad. Sci. (Wash.), 92, 5674-5678 (1995).
28. STORKUS, W.J., ZEH, H.J. 3d, MAEURER, M.J., SALTER, R.D. and LOTZE, M.T., Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J. Immunol., 151, 3719-3727 (1993).
29. TJANDRAWAN, T., MARTIN, D.M., MAEURER, MJ., CASTELLI, C., LOTZE, M.T. and STORKUS, W.J., Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTL in vitro. J. Immunother., 21, 149-157 (1998).
30. TSOMIDES, T.J., REILLY, E.B. and EISEN, H.N., Anti-melanoma cytotoxic T-lymphocytes (CTL) recognize numerous antigenic peptides having "self" sequences: autoimmune nature of the anti-melanoma CTL response. Int. Immunol., 9, 327-338 (1997).
31. VALITUTTI, S., MULLER, S., CELLA, M., PADOVAN, E. and LANZAVECCHIA, A., Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature, 375, 148-151 (1995).
32. VALMORI, D., FONTENEAU, J.F., LIZANA, C.M., GERVOIS, N., LIÉNARD, D., RIMOLDI, D., JONGENEEL, V., JOTEREAU, F., CEROTTINI, J.C. and ROMERO, P., Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol., 160, 1750-1758 (1998).
33. ZAL, T., WEISS, S., MELLOR, A. and STOCKINGER, B., Expression of a second receptor rescues self-specific T cells from thymic deletion and allows activation of autoreactive effector function. Proc. nat. Acad. Sci. (Wash.), 93, 9102-9107 (1996).